Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.67 | N/A | +1.52% |
management commentary, guidance changes, and full analysis available with Pro.
| +1.52% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to core business operations. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
We continue to focus on our core business areas.
Pfizer's earnings report showed a slight beat on EPS, which indicates some operational success. However, the stock reacted negatively, declining by 0.24%. This could suggest that investors were looking for more comprehensive guidance or stronger revenue figures, which were not disclosed in this report.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Jul 31, 2017